Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05491083 | Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer | PHASE1 | RECRUITING | 51 | — | — | Jun 12, 2023 | Dec 31, 2026 | Jul 25, 2025 | 1 | Singapore |
Toxicities will be graded using the Common Terminology Criteria for Adverse Events (CTCAE) toxicity grading Version 5
Complete and partial clinical response will be measured by RECIST 1.1.
| Arm | Type | Description |
|---|---|---|
| Phase 1b Pembrolizumab & ADG106 | EXPERIMENTAL | Intravenous Pembrolizumab + ADG106 on day 1 of each 3-weekly cycle |
| Phase 2 Pembrolizumab & ADG106 | EXPERIMENTAL | Intravenous Pembrolizumab + ADG106 each 3-weekly cycle |
| Name | Type | Description |
|---|---|---|
| Pembrolizumab & ADG106 (Phase Ib) | DRUG | Drug: ADG106 Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated. Pembrolizumab Administered as an intravenous infusion over 30 minutes |
| Pembrolizumab & ADG106 (Phase II) | DRUG | Drug: ADG106 Administered as an intravenous infusion over 60-90 minutes in the initial cycle and over 30 minutes in subsequent cycle if well tolerated. Pembrolizumab Administered as an intravenous infusion over 30 minutes |
Inclusion Criteria: * 21 years and above of age * Estimated life expectancy of at least 12 weeks. * Has recovered from acute toxicities from prior anti-cancer therapies. * Has a tumor lesion that can be safely biopsied and who is willing to undergo tumor biopsy at baseline before starting study tre...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |